Patrick Reichl

Patrick Reichl has a background in genetics and biology, with a focus on toxicological risk assessments and nonclinical development. Patrick has held positions as a Research Scientist and Senior Scientific Professional at various companies including Croma Pharma and Shire. Patrick is currently serving as the Toxicology Lead for Nonclinical Development & CMC at Croma Pharma, where Patrick oversees non-clinical strategies for regulatory submissions of Class III medical devices. Their expertise lies in scientific evaluation of projects and toxicological risk assessments for pharmaceuticals, materials, and impurities. Patrick holds a PhD in Biology from the University of Vienna, along with a MSc in Toxicology and MSc in Genetics from other institutions.